"Immonocal", "Bioperine", and pomegranate juice
This post not CC'd by email
Quote:
>Finally, I have just reviewed articles in medical journals suggesting
>that pomegranate juice was effective in reduction of cardiovascular
>plaque in mice and in reduction of cholesterol in human subjects.
>Any comments or opinions regarding the foregoing will be greatly
>appreciated!!
G'day G'day Ron,
First a welcome to sci.med.nutrition. My apologies if I haven't
noticed you in some thread I wasn't following.
Second an opinion. It helps the flow of a thread to have one topic
not three. Some of the regulars have various mono-manias and can only
obsess about one thing at a time.
Third. Pomegranate juice has a delightful distinctive flavour that
goes nicely in salad dressing with a hint of orange blossom. Nice to
know it might conceivably be beneficial as well. If don't tell them
it is good for them they will keep on eating it. <grin>
I assume this is the abstract.
1: J Nutr 2001 Aug;131(8):2082-9
Pomegranate juice supplementation to atheroscl{*filter*} mice reduces
macrophage lipid peroxidation, cellular cholesterol accumulation and
development of atherosclerosis.
Kaplan M, Hayek T, Raz A, Coleman R, Dornfeld L, Vaya J, Aviram M.
The Lipid Research Laboratory, Bruce Rappaport Faculty of Medicine,
Technion, The Rappaport Family Institute for Research in the Medical
Sciences and Rambam Medical Center, Haifa 31096, Israel.
Inhibition of lipid peroxidation contributes to the attenuation of
macrophage cholesterol accumulation, foam-cell formation and
atherosclerosis. Evidence suggests that nutritional antioxidants such
as pomegranate juice (PJ) can contribute to the reduction of oxidative
stress and atherogenesis. The goals of the present study were to
determine whether such beneficial effects of PJ exist when
supplemented to apolipoprotein E-deficient (E(0)) mice with advanced
atherosclerosis and to analyze the antiatheroscl{*filter*} activity of a
tannin-fraction isolated from PJ. Mice (4-mo-old) were supplemented
with PJ in their drinking water for 2 mo and compared with age-matched
placebo-treated mice, as well as to young (4-mo-old) control mice, for
their mouse peritoneal macrophage (MPM) oxidative state, cholesterol
flux and mice atheroscl{*filter*} lesion size. PJ supplementation reduced
each of the proatherogenic variables determined in the present study
compared with age-matched placebo-treated mice. It significantly
induced serum paraoxonase activity and reduced MPM lipid peroxide
content compared with placebo-treated mice and control mice. PJ
administration to E(0) mice significantly reduced the oxidized
(Ox)-LDL MPM uptake by 31% and MPM cholesterol esterification and
increased macrophage cholesterol efflux by 39% compared with
age-matched, placebo-treated mice. PJ consumption reduced macrophage
Ox-LDL uptake and cholesterol esterification to levels lower than
those in 4-mo-old, unsupplemented controls. PJ supplementation to E(0)
mice with advanced atherosclerosis reduced the lesion size by 17%
compared with placebo-treated mice. In a separate study,
supplementation of young (2-mo-old) E(0) mice for 2 mo with a tannin
fraction isolated from PJ reduced their atheroscl{*filter*} lesion size,
paralleled by reduced plasma lipid peroxidation and decreased Ox-LDL
MPM uptake. PJ supplementation to mice with advanced atherosclerosis
reduced their macrophage oxidative stress, their macrophage
cholesterol flux and even attenuated the development of
atherosclerosis. Moreover, a tannin-fraction isolated from PJ had a
significant antiatheroscl{*filter*} activity.
PMID: 11481398 [PubMed - in process]
--
Quentin Grady ^ ^ /
New Zealand, >#,#< [
/ \ /\
"... and the blind dog was leading."
http://www.***.com/
